
Fractyl Health, Inc. (NASDAQ:GUTS – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Fractyl Health in a report released on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($3.64) for the year, up from their previous estimate of ($5.88). The consensus estimate for Fractyl Health’s current full-year earnings is ($5.88) per share. HC Wainwright also issued estimates for Fractyl Health’s Q4 2026 earnings at ($0.86) EPS, FY2027 earnings at ($4.66) EPS, FY2028 earnings at ($3.04) EPS, FY2029 earnings at $0.84 EPS and FY2030 earnings at $3.95 EPS.
A number of other brokerages have also recently weighed in on GUTS. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Morgan Stanley decreased their target price on Fractyl Health to $4.00 and set an “equal weight” rating on the stock in a research note on Monday, October 19th. Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Craig Hallum set a $5.00 target price on Fractyl Health in a report on Monday, October 19th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Fractyl Health currently has an average rating of “Hold” and an average target price of $50.25.
Get Our Latest Stock Report on GUTS
Fractyl Health Trading Up 9.8%
GUTS opened at $0.99 on Tuesday. Fractyl Health has a 52 week low of $0.80 and a 52 week high of $29.34. The business has a fifty day simple moving average of $3.75 and a 200-day simple moving average of $6.76. The firm has a market cap of $13.15 million, a P/E ratio of -0.32 and a beta of 2.90. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.43.
Institutional Investors Weigh In On Fractyl Health
A number of hedge funds have recently added to or reduced their stakes in GUTS. Nantahala Capital Management LLC acquired a new stake in Fractyl Health during the 2nd quarter worth approximately $8,968,058. Bank of America Corp DE acquired a new position in shares of Fractyl Health in the second quarter worth $4,791,000. Pale Fire Capital SE grew its stake in shares of Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after acquiring an additional 2,711,103 shares in the last quarter. General Catalyst Group Management LLC acquired a new position in shares of Fractyl Health in the second quarter worth $3,880,000. Finally, BlackRock Inc. purchased a new stake in shares of Fractyl Health during the second quarter worth $1,431,000.
Fractyl Health Company Profile
Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.
Further Reading
- Five stocks we like better than Fractyl Health
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
